Patents by Inventor Bruno Figueroa

Bruno Figueroa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CELL CULTURE PROCESS
    Publication number: 20230416674
    Abstract: A cell culture medium comprising tyrosine at a concentration of at least 3 mM and polyvinylalcohol (PVA).
    Type: Application
    Filed: August 31, 2023
    Publication date: December 28, 2023
    Applicant: Pfizer Inc.
    Inventors: Bruno FIGUEROA, Yen-Tung Luan, Wenge Wang
  • METHODS OF GLYCOENGINEERING PROTEOGLYCANS WITH DISTINCT GLYCAN STRUCTURES
    Publication number: 20210115413
    Abstract: Disclosed herein are methods of generating proteoglycans with distinct glycan structures in engineered, non-naturally occurring eukaryotic cells. These methods make accessible a dynamic range of protein glycosylation. Compositions of engineered, non-naturally occurring cells capable of generating these proteoglycans are also disclosed herein.
    Type: Application
    Filed: June 20, 2019
    Publication date: April 22, 2021
    Applicants: Massachusetts Institute of Technology, Pfizer Inc.
    Inventors: Michelle Chang, Leonid A. Gaydukov, Giyoung Jung, Nevin M. Summers, Timothy Kuan-Ta Lu, Ron Weiss, John Scarcelli, Richard Cornell, Jeffrey Marshall, Bruno Figueroa, Wen Allen Tseng
  • CELL CULTURE PROCESS
    Publication number: 20190112572
    Abstract: A cell culture medium comprising tyrosine at a concentration of at least 3 mM and polyvinylalcohol (PVA).
    Type: Application
    Filed: March 23, 2017
    Publication date: April 18, 2019
    Applicant: Pfizer Inc.
    Inventors: Bruno FIGUEROA, Yen-Tung Luan, Wenge Wang
  • Inhibition of apoptosis process and improvement of cell performance
    Patent number: 7604989
    Abstract: The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of a cell-related product by expressing one or more anti-apoptotic polypeptides in a cell such that production of the cell-related product by the cell is increased. Recombinant cells useful for producing cell-related product or cellular therapy are also provided.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: October 20, 2009
    Assignees: Johns Hopkins University, Biogen Idec Inc.
    Inventors: Mitchell Reff, Eric Ailor, Michael J. Betenbaugh, Bruno Figueroa, Jr., Marie Hardwick
  • Inhibition of apoptosis process and improvement of cell performance
    Publication number: 20030064510
    Abstract: The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of a cell-related product by expressing one or more anti-apoptotic polypeptides in a cell such that production of the cell-related product by the cell is increased. Recombinant cells useful for producing cell-related product or cellular therapy are also provided.
    Type: Application
    Filed: July 10, 2002
    Publication date: April 3, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Mitchell E. Reff, Eric Ailor, Michael J. Betenbaugh, Bruno Figueroa, Marie Hardwick